Inhibikase Therapeutics (IKT) EBIT Margin Growth (3y) (2023)

Inhibikase Therapeutics (IKT) EBIT Margin Growth (3y) (2023) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin Growth (3y) (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 9,942.00
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 530.00
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn -1,211.00
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 7,794.00
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Inhibikase Therapeutics 407.51 Mn 237.14 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2023 -44.04 Bn
Sep 30, 2023 -423,195.00
Jun 30, 2023 -513,956.00
Mar 31, 2023 -710,819.00